文献速递神经核医学放射性药物与辐射防护

[18F]PR04.MZ的全身生物分布与辐射剂量学:一种用于运动障碍患者临床管理的新型PET放射性示踪剂

Whole-body biodistribution and radiation dosimetry of [18F]PR04.MZ: a new PET radiotracer for clinical management of patients with movement disorders.
PubMed 文献 · EJNMMI Res · 2022-01-10

本研究纳入6名健康受试者(男3名、女3名),注射200 ± 11 MBq [18F]PR04.MZ后至5.5小时行系列全身PET/CT扫描,评估其生物分布与辐射剂量学。结果显示示踪剂主要经肝胆排泄,胆囊壁归一化吸收剂量最高(32.2 ± 6.4 µGy/MBq),ICRP 60和103有效剂量分别为16.3 ± 1.1和16.6 ± 1.5 µSv/MBq。作者认为其剂量学特征良好,与其他18F标记PET示踪剂相当,适合更大规模的临床应用。

要点

  • 6名健康受试者注射200 ± 11 MBq [18F]PR04.MZ后行14次全身PET/CT扫描至5.5小时
  • 胆囊壁归一化吸收剂量最高,为32.2 ± 6.4 µGy/MBq
  • ICRP 60和103有效剂量分别为16.3 ± 1.1和16.6 ± 1.5 µSv/MBq

核心结论

  • [18F]PR04.MZ具有良好的剂量学特征,与其他18F标记PET示踪剂相当,适合更大规模的临床应用。

研究设计与样本

  • 研究纳入6名健康受试者(男3名、女3名),注射200 ± 11 MBq [18F]PR04.MZ后至5.5小时共采集14次全身PET/CT扫描。
  • 图像刚性配准后在CT或PET图像上勾画感兴趣体积,计算选定源器官的时间积分活度系数,采用IDAC-Dose 2.1计算器官吸收剂量和有效剂量。

主要发现

  • [18F]PR04.MZ的生理性摄取主要见于纹状体、脑、肝脏、胆囊、肠道、红骨髓和皮质骨。
  • 示踪剂主要经肝胆清除,较少程度经肾清除。
  • 归一化吸收剂量最高为胆囊壁32.2 ± 6.4 µGy/MBq,其次为膀胱壁27.2 ± 4.5 µGy/MBq、红骨髓26.5 ± 1.4 µGy/MBq、皮质骨表面26.3 ± 2.5 µGy/MBq、肝脏22.5 ± 1.8 µGy/MBq和肾脏21.8 ± 1.1 µGy/MBq。
  • 按ICRP 60和ICRP 103计算的有效剂量分别为16.3 ± 1.1和16.6 ± 1.5 µSv/MBq。

临床怎么用

  • 原文结论认为[18F]PR04.MZ剂量学特征良好、与其他18F标记PET示踪剂相当,适合更大规模的临床应用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: [18F]PR04.MZ is a new PET imaging agent for dopamine transporters, providing excellent image quality and allowing for the evaluation of patients with movement disorders such as Parkinson's disease. The objective of this study was to evaluate the biodistribution and radiation dosimetry of [18F]PR04.MZ by serial PET imaging. METHODS: Six healthy subjects (n = 3 males, n = 3 females) were enrolled in this study. A series of 14 whole-body PET/CT scans were acquired until 5.5 h post-injection of 200 ± 11 MBq of [18F]PR04.MZ. After rigid co-registration, volumes of interest were outlined either on CT or PET images. Time-integrated activity coefficients were calculated for selected source organs. Organ absorbed doses, and the effective dose were calculated using IDAC-Dose 2.1. RESULTS: Physiological uptake of [18F]PR04.MZ was mainly observed in the striatum, brain, liver, gall bladder, intestine, red marrow and cortical bone. [18F]PR04.MZ was primarily excreted via hepatobiliary clearance and, to a lower extent, via renal clearance. The normalized absorbed doses were highest in gall bladder wall (32.2 ± 6.4 µGy/MBq), urinary bladder wall (27.2 ± 4.5 µGy/MBq), red marrow (26.5 ± 1.4 µGy/MBq), cortical bone surface (26.3 ± 2.5 µGy/MBq), liver (22.5 ± 1.8 µGy/MBq) and kidneys (21.8 ± 1.1 µGy/MBq). The effective dose according to ICRP 60 and 103 was 16.3 ± 1.1 and 16.6 ± 1.5 µSv/MBq, respectively. CONCLUSION: [18F]PR04.MZ has a favourable dosimetry profile, comparable to those of other 18F-labelled PET tracers, and is suitable for larger clinical applications. Trial registration CEC SSM Oriente, Santiago, Chile, permit 20140520.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Lehnert W, Riss PJ, Hurtado de Mendoza A, et al. Whole-body biodistribution and radiation dosimetry of [18F]PR04.MZ: a new PET radiotracer for clinical management of patients with movement disorders. EJNMMI Res. 2022. PMID: 35006412. doi:10.1186/s13550-021-00873-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。